VENTANA MMR RxDx Panel (Endometrial Cancer with dMMR status)

FDA Premarket Approval P200019 S005

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

DeviceVENTANA MMR RxDx Panel (Endometrial Cancer with dMMR status)
Generic NameImmunohistochemistry Test, Dna Mismatch Repair (mmr) Protein Assay
ApplicantVentana Medical Systems1910 E Innovation Park Drivetucson, AZ 85755 PMA NumberP200019 Supplement NumberS005 Date Received07/12/2022 Decision Date07/29/2022 Product Code QNH  Advisory Committee Pathology Supplement Type30-day Notice Supplement Reason Process Change - Manufacturer/sterilizer/packager/supplier Expedited Review Granted? No
Date Received2022-07-12
Decision Date2022-07-29
PMAP200019
SupplementS005
Product CodeQNH 
Advisory CommitteePathology
Supplement Type30-day Notice
Supplement ReasonProcess Change - Manufacturer/sterilizer/packager/supplier
Expedited ReviewNo
Combination ProductNo
Applicant AddressVentana Medical Systems
1910 E Innovation Park Drive
tucson, AZ 85755 PMA NumberP200019 Supplement NumberS005 Date Received07/12/2022 Decision Date07/29/2022 Product Code QNH  Advisory Committee Pathology Supplement Type30-day Notice Supplement Reason Process Change - Manufacturer/sterilizer/packager/supplier Expedited Review Granted? No Combination ProductNo Approval Order Statement  
addition Of Alternative Suppliers For Component Parts

Supplemental Filings

Supplement NumberDateSupplement Type
P200019Original Filing
S005 2022-07-12 30-day Notice
S004 2022-02-16 Special (immediate Track)
S003 2022-01-28 135 Review Track For 30-day Notice
S002
S001

© 2022 FDA.report
This site is not affiliated with or endorsed by the FDA.